Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know

References

1. 1.↵
   1. Lin D,
   2. Wang M,
   3. Chen Y, et al

   . Trends in intracranial glioma incidence and mortality in the United States, 1975-2018. Front Oncol 2021;11:748061 doi:10.3389/fonc.2021.748061 pmid:34790574

   CrossRefPubMed
2. 2.↵
   1. Ostrom QT,
   2. Gittleman H,
   3. Liao P, et al

   . CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol 2017;19:v1–88 doi:10.1093/neuonc/nox158 pmid:29117289

   CrossRefPubMed
3. 3.↵
   1. Law I,
   2. Albert NL,
   3. Arbizu J, et al

   . Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 2019;46:540–57 doi:10.1007/s00259-018-4207-9 pmid:30519867

   CrossRefPubMed
4. 4.↵
   1. Soni N,
   2. Ora M,
   3. Mohindra N, et al

   . Diagnostic performance of PET and perfusion-weighted imaging in differentiating tumor recurrence or progression from radiation necrosis in posttreatment gliomas: a review of literature. AJNR Am J Neuroradiol 2020;41:1550–57 doi:10.3174/ajnr.A6685 pmid:32855194

   Abstract/FREE Full Text
5. 5.↵
   1. de Zwart PL,
   2. van Dijken BR,
   3. Holtman GA, et al

   . Diagnostic accuracy of PET tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and metaanalysis. J Nucl Med 2020;61:498–504 doi:10.2967/jnumed.119.233809 pmid:31541032

   Abstract/FREE Full Text
6. 6.↵
   1. Cui M,
   2. Zorrilla-Veloz RI,
   3. Hu J, et al

   . Diagnostic accuracy of PET for differentiating true glioma progression from post treatment-related changes: a systematic review and meta-analysis. Front Neurol 2021;12:671867 doi:10.3389/fneur.2021.671867 pmid:34093419

   CrossRefPubMed
7. 7.↵
   1. Moreau A,
   2. Febvey O,
   3. Mognetti T, et al

   . Contribution of different positron emission tomography tracers in glioma management: focus on glioblastoma. Front Oncol 2019;9:9 doi:10.3389/fonc.2019.01134 pmid:31737567

   CrossRefPubMed
8. 8.↵
   1. Lopes C,
   2. Pereira C,
   3. Medeiros R

   . ASCT2 and LAT1 contribution to the hallmarks of cancer: from a molecular perspective to clinical translation. Cancers (Basel) 2021;13:203 doi:10.3390/cancers13020203 pmid:33429909

   CrossRefPubMed
9. 9.↵
   1. Hughes KL,
   2. O’Neal CM,
   3. Andrews BJ, et al

   . A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma. Neurooncol Adv 2021;3:vdab003 doi:10.1093/noajnl/vdab003 pmid:34409294

   CrossRefPubMed
10. 10.↵
    1. Fuchs BC,
    2. Bode BP

    . Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 2005;15:254–66 doi:10.1016/j.semcancer.2005.04.005 pmid:15916903

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Jansen NL,
    2. Suchorska B,
    3. Wenter V, et al

    . Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med 2014;55:198–203 doi:10.2967/jnumed.113.122333 pmid:24379223

    Abstract/FREE Full Text
12. 12.↵
    1. Jansen NL,
    2. Graute V,
    3. Armbruster L, et al

    . MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 2012;39:1021–29 doi:10.1007/s00259-012-2109-9 pmid:22491781

    CrossRefPubMed
13. 13.↵
    1. Jansen NL,
    2. Schwartz C,
    3. Graute V, et al

    . Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol 2012;14:1473–80 doi:10.1093/neuonc/nos259 pmid:23090986

    CrossRefPubMed
14. 14.↵
    1. Brendle C,
    2. Maier C,
    3. Bender B, et al

    . Impact of (18)F-FET PET/MRI on clinical management of brain tumor patients. J Nucl Med 2022;63:522–27 doi:10.2967/jnumed.121.262051 pmid:34353870

    Abstract/FREE Full Text
15. 15.↵
    1. Furtak J,
    2. Rakowska J,
    3. Szylberg T, et al

    . Glioma biopsy based on hybrid dual time-point FET-PET/MRI: a proof of concept study. Front Neurol 2021;12:634609 doi:10.3389/fneur.2021.634609 pmid:34046002

    CrossRefPubMed
16. 16.↵
    1. Göttler J,
    2. Lukas M,
    3. Kluge A, et al

    . Intra-lesional spatial correlation of static and dynamic FET-PET parameters with MRI-based cerebral blood volume in patients with untreated glioma. Eur J Nucl Med Mol Imaging 2017;44:392–97 doi:10.1007/s00259-016-3585-0 pmid:27913827

    CrossRefPubMed
17. 17.↵
    1. Ort J,
    2. Hamou HA,
    3. Kernbach JM, et al

    . (18)F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection. J Neurooncol 2021;155:71–80 doi:10.1007/s11060-021-03844-1 pmid:34599479

    CrossRefPubMed
18. 18.↵
    1. Xiao J,
    2. Jin Y,
    3. Nie J, et al

    . Diagnostic and grading accuracy of (18)F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis. BMC Cancer 2019;19:767 doi:10.1186/s12885-019-5938-0 pmid:31382920

    CrossRefPubMed
19. 19.↵
    1. Verger A,
    2. Filss CP,
    3. Lohmann P, et al

    . Comparison of (18)F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study. Eur J Nucl Med Mol Imaging 2017;44:2257–65 doi:10.1007/s00259-017-3812-3 pmid:28831534

    CrossRefPubMed
20. 20.↵
    1. Girard A,
    2. Le Reste PJ,
    3. Metais A, et al

    . Combining (18)F-DOPA PET and MRI with perfusion-weighted imaging improves delineation of high-grade subregions in enhancing and non-enhancing gliomas prior treatment: a biopsy-controlled study. J Neurooncol 2021;155:287–95 doi:10.1007/s11060-021-03873-w pmid:34686993

    CrossRefPubMed
21. 21.↵
    1. Osborn AG,
    2. Louis DN,
    3. Poussaint TY, et al

    . The 2021 World Health Organization Classification of Tumors of the Central Nervous System: what neuroradiologists need to know. AJNR Am J Neuroradiol 2022;43:928–37 doi:10.3174/ajnr.A7462 pmid:35710121

    Abstract/FREE Full Text
22. 22.↵
    1. Song S,
    2. Wang L,
    3. Yang H, et al

    . Static (18)F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status. Eur Radiol 2021;31:4087–96 doi:10.1007/s00330-020-07470-9 pmid:33211141

    CrossRefPubMed
23. 23.↵
    1. Tatekawa H,
    2. Yao J,
    3. Oughourlian TC, et al

    . Maximum uptake and hypermetabolic volume of 18F-FDOPA PET estimate molecular status and overall survival in low-grade gliomas: a PET and MRI study. Clin Nucl Med 2020;45:e505–11 doi:10.1097/RLU.0000000000003318 pmid:33031233

    CrossRefPubMed
24. 24.↵
    1. Kim D,
    2. Chun JH,
    3. Kim SH, et al

    . Re-evaluation of the diagnostic performance of (11)C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas. Eur J Nucl Med Mol Imaging 2019;46:1678–84 doi:10.1007/s00259-019-04337-0 pmid:31102001

    CrossRefPubMed
25. 25.↵
    1. Cheng Y,
    2. Song S,
    3. Wei Y, et al

    . Glioma imaging by O-(2-18F-fluoroethyl)-L-tyrosine PET and diffusion-weighted MRI and correlation with molecular phenotypes, validated by PET/MR-guided biopsies. Front Oncol 2021;11:743655 doi:10.3389/fonc.2021.743655 pmid:34912706

    CrossRefPubMed
26. 26.↵
    1. Haubold J,
    2. Demircioglu A,
    3. Gratz M, et al

    . Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric (18)F-FET PET-MRI and MR fingerprinting. Eur J Nucl Med Mol Imaging 2020;47:1435–45 doi:10.1007/s00259-019-04602-2 pmid:31811342

    CrossRefPubMed
27. 27.↵
    1. Meyer HS,
    2. Liesche-Starnecker F,
    3. Mustafa M, et al

    . (18)F FET PET uptake indicates high tumor and low necrosis content in brain metastasis. Cancers (Basel) 2021;13:355 doi:10.3390/cancers13020355 pmid:33478030

    CrossRefPubMed
28. 28.↵
    1. Laack NN,
    2. Pafundi D,
    3. Anderson SK, et al

    . Initial results of a Phase 2 trial of (18)F-DOPA PET-guided dose-escalated radiation therapy for glioblastoma. Int J Radiat Oncol Biol Phys 2021;110:1383–95 doi:10.1016/j.ijrobp.2021.03.032 pmid:33771703

    CrossRefPubMed
29. 29.↵
    1. Dissaux G,
    2. Dissaux B,
    3. Kabbaj OE, et al

    . Radiotherapy target volume definition in newly diagnosed high grade glioma using (18)F-FET PET imaging and multiparametric perfusion MRI: a prospective study (IMAGG). Radiother Oncol 2020;150:164–71 doi:10.1016/j.radonc.2020.06.025 pmid:32580001

    CrossRefPubMed
30. 30.↵
    1. Filss CP,
    2. Galldiks N,
    3. Stoffels G, et al

    . Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med 2014;55:540–45 doi:10.2967/jnumed.113.129007 pmid:24578243

    Abstract/FREE Full Text
31. 31.↵
    1. Lohmann P,
    2. Stavrinou P,
    3. Lipke K, et al

    . FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging 2019;46:591–602 doi:10.1007/s00259-018-4188-8 pmid:30327856

    CrossRefPubMed
32. 32.↵
    1. Hayes AR,
    2. Jayamanne D,
    3. Hsiao E, et al

    . Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Pract Radiat Oncol 2018;8:230–38 doi:10.1016/j.prro.2018.01.006 pmid:29730279

    CrossRefPubMed
33. 33.↵
    1. Kläsner B,
    2. Buchmann N,
    3. Gempt J, et al

    . Early [18F]FET-PET in gliomas after surgical resection: comparison with MRI and histopathology. PLoS One 2015;10:e0141153 doi:10.1371/journal.pone.0141153 pmid:26502297

    CrossRefPubMed
34. 34.↵
    1. Seidlitz A,
    2. Beuthien-Baumann B,
    3. Löck S, et al

    . Final results of the Prospective Biomarker Trial PETra: [(11)C]-MET-accumulation in postoperative PET/MRI predicts outcome after radiochemotherapy in glioblastoma. Clin Cancer Res 2021;27:1351–60 doi:10.1158/1078-0432.CCR-20-1775 pmid:33376095

    Abstract/FREE Full Text
35. 35.↵
    1. Rosen J,
    2. Stoffels G,
    3. Lohmann P, et al

    . Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement. Sci Rep 2021;11:20828 doi:10.1038/s41598-021-00193-x pmid:34675225

    CrossRefPubMed
36. 36.↵
    1. Ellingson BM,
    2. Chung C,
    3. Pope WB, et al

    . Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 2017;134:495–504 doi:10.1007/s11060-017-2375-2 pmid:28382534

    CrossRefPubMed
37. 37.↵
    1. Albert NL,
    2. Weller M,
    3. Suchorska B, et al

    . Response Assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 2016;18:1199–208 doi:10.1093/neuonc/now058 pmid:27106405

    CrossRefPubMed
38. 38.↵
    1. Galldiks N,
    2. Niyazi M,
    3. Grosu AL, et al

    . Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients: a report of the PET/RANO group. Neuro Oncol 2021;23:881–93 doi:10.1093/neuonc/noab013 pmid:33538838

    CrossRefPubMed
39. 39.↵
    1. Deuschl C,
    2. Kirchner J,
    3. Poeppel TD, et al

    . 11C-MET PET/MRI for detection of recurrent glioma. Eur J Nucl Med Mol Imaging 2018;45:593–601 doi:10.1007/s00259-017-3916-9 pmid:29282517

    CrossRefPubMed
40. 40.↵
    1. D’Souza MM,
    2. Sharma R,
    3. Jaimini A, et al

    . 11C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas. Clin Nucl Med 2014;39:791–98 doi:10.1097/RLU.0000000000000532 pmid:25036022

    CrossRefPubMed
41. 41.↵
    1. Steidl E,
    2. Langen KJ,
    3. Hmeidan SA, et al

    . Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes. Eur J Nucl Med Mol Imaging 2021;48:1956–65 doi:10.1007/s00259-020-05114-0 pmid:33241456

    CrossRefPubMed
42. 42.↵
    1. Werner JM,
    2. Weller J,
    3. Ceccon G, et al

    . Diagnosis of pseudoprogression following lomustine-temozolomide chemoradiation in newly diagnosed glioblastoma patients using FET-PET. Clin Cancer Res 2021;27:3704–13 doi:10.1158/1078-0432.CCR-21-0471 pmid:33947699

    Abstract/FREE Full Text
43. 43.↵
    1. Pellerin A,
    2. Khalifé M,
    3. Sanson M, et al

    . Simultaneously acquired PET and ASL imaging biomarkers may be helpful in differentiating progression from pseudo-progression in treated gliomas. Eur Radiol 2021;31:7395–405 doi:10.1007/s00330-021-07732-0 pmid:33787971

    CrossRefPubMed
44. 44.↵
    1. Prather KY,
    2. O’Neal CM,
    3. Westrup AM, et al

    . A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma. Neurooncol Adv 2022;4:vdac008 doi:10.1093/noajnl/vdac008 pmid:35300149

    CrossRefPubMed
45. 45.↵
    1. Harris RJ,
    2. Cloughesy TF,
    3. Pope WB, et al

    . 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 2012;14:1079–89 doi:10.1093/neuonc/nos141 pmid:22711609

    CrossRefPubMed
46. 46.↵
    1. Lombardi G,
    2. Spimpolo A,
    3. Berti S, et al

    . PET/MR in recurrent glioblastoma patients treated with regorafenib: [(18)F]FET and DWI-ADC for response assessment and survival prediction. Br J Radiol 2022;95:20211018 doi:10.1259/bjr.20211018 pmid:34762492

    CrossRefPubMed
47. 47.↵
    1. Kristin Schmitz A,
    2. Sorg RV,
    3. Stoffels G, et al

    . Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine ((18)F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients. Br J Neurosurg 2021;35:736–42 doi:10.1080/02688697.2019.1639615 pmid:31407920

    CrossRefPubMed
48. 48.↵
    1. Wirsching HG,
    2. Roelcke U,
    3. Weller J, et al

    . MRI and (18)FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with isocitrate dehydrogenase wild-type glioblastoma: results from the randomized ARTE Trial. Clin Cancer Res 2021;27:179–88 doi:10.1158/1078-0432.CCR-20-2096 pmid:32967939

    Abstract/FREE Full Text
49. 49.↵
    1. Niyazi M,
    2. Brada M,
    3. Chalmers AJ, et al

    . ESTRO-ACROP guideline “target delineation of glioblastomas.” Radiother Oncol 2016;118:35–42 doi:10.1016/j.radonc.2015.12.003 pmid:26777122

    CrossRefPubMed
50. 50.↵
    1. Ekici S,
    2. Nye JA,
    3. Neill SG, et al

    . Glutamine imaging: a new avenue for glioma management. AJNR Am J Neuroradiol 2022;43:11–18 doi:10.3174/ajnr.A7333 pmid:34737183

    Abstract/FREE Full Text
51. 51.↵
    1. Anderson NM,
    2. Simon MC

    . The tumor microenvironment. Curr Biol 2020;30:R921–25 doi:10.1016/j.cub.2020.06.081 pmid:32810447

    CrossRefPubMed
52. 52.↵
    1. Zinnhardt B,
    2. Müther M,
    3. Roll W, et al

    . TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. Neuro Oncol 2020;22:1030–43 doi:10.1093/neuonc/noaa023 pmid:32047908

    CrossRefPubMed
53. 53.↵
    1. Leimgruber A,
    2. Hickson K,
    3. Lee ST, et al

    . Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse. Eur J Nucl Med Mol Imaging 2020;47:1476–85 doi:10.1007/s00259-020-04706-0 pmid:32025750

    CrossRefPubMed
54. 54.↵
    1. Barajas RF Jr.,
    2. Ambady P,
    3. Link J, et al

    . [(18)F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab. Neurooncol Pract 2022;9:246–50 doi:10.1093/nop/npac021 pmid:35601969

    CrossRefPubMed
55. 55.↵
    1. Unterrainer M,
    2. Fleischmann DF,
    3. Vettermann F, et al

    . TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative (18)F-GE-180 PET study. Eur J Nucl Med Mol Imaging 2020;47:1368–80 doi:10.1007/s00259-019-04491-5 pmid:31486876

    CrossRefPubMed
56. 56.↵
    1. Echavidre W,
    2. Picco V,
    3. Faraggi M, et al

    . Integrin-αvβ3 as a therapeutic target in glioblastoma: back to the future? Pharmaceutics 2022;14:1054 doi:10.3390/pharmaceutics14051053 pmid:35631639

    CrossRefPubMed
57. 57.↵
    1. Rohrich M,
    2. Loktev A,
    3. Wefers AK, et al

    . IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Eur J Nucl Med Mol Imaging 2019;46:2569–80 doi:10.1007/s00259-019-04444-y pmid:31388723

    CrossRefPubMed
58. 58.↵
    1. Lohmann P,
    2. Meißner AK,
    3. Kocher M, et al

    . Feature-based PET/MRI radiomics in patients with brain tumors. Neurooncol Adv 2020;2:iv15–21 doi:10.1093/noajnl/vdaa118 pmid:33521637

    CrossRefPubMed
59. 59.↵
    1. Lohmann P,
    2. Lerche C,
    3. Bauer EK, et al

    . Predicting IDH genotype in gliomas using FET PET radiomics. Sci Rep 2018;8:13328 doi:10.1038/s41598-018-31806-7 pmid:30190592

    CrossRefPubMed
60. 60.↵
    1. Russo G,
    2. Stefano A,
    3. Alongi P, et al

    . Feasibility on the use of radiomics features of 11[C]-MET PET/CT in central nervous system tumours: preliminary results on potential grading discrimination using a machine learning model. Curr Oncol 2021;28:5318–31 doi:10.3390/curroncol28060444 pmid:34940083

    CrossRefPubMed
61. 61.↵
    1. Carles M,
    2. Popp I,
    3. Starke MM, et al

    . FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation? Radiat Oncol 2021;16:46 doi:10.1186/s13014-020-01744-8 pmid:33658069

    CrossRefPubMed
62. 62.↵
    1. Langen KJ,
    2. Galldiks N

    . Update on amino acid pet of brain tumours. Curr Opin Neurol 2018;31:354–61 doi:10.1097/WCO.0000000000000574 pmid:29952832

    CrossRefPubMed
63. 63.↵
    1. Langen K-J,
    2. Heinzel A,
    3. Lohmann P, et al

    . Advantages and limitations of amino acid PET for tracking therapy response in glioma patients. Expert Rev Neurother.2020;20:137–46 doi:10.1080/14737175.2020.1704256 pmid:31829748

    CrossRefPubMed
64. 64.↵
    1. Heinzel A,
    2. Stock S,
    3. Langen K-J, et al

    . Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imaging 2012;39:1089–96 doi:10.1007/s00259-012-2093-0 pmid:22419257

    CrossRefPubMed
65. 65.↵
    1. Heinzel A,
    2. Müller D,
    3. Langen KJ, et al

    . The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. J Nucl Med 2013;54:1217–22 doi:10.2967/jnumed.113.120089 pmid:23785172

    Abstract/FREE Full Text
66. 66.↵
    1. Baguet T,
    2. Verhoeven J,
    3. De Vos F, et al

    . Cost-effectiveness of [18F] fluoroethyl-L-tyrosine for temozolomide therapy assessment in patients with glioblastoma. Front Oncol 2019;9:9 doi:10.3389/fonc.2019.00814

    CrossRefPubMed
67. 67.↵
    1. Ehman EC,
    2. Johnson GB,
    3. Villanueva-Meyer JE, et al

    . PET/MRI: Where might it replace PET/CT? J Magn Reson Imaging 2017;46:1247–62 doi:10.1002/jmri.25711 pmid:28370695

    CrossRefPubMed
68. 68.↵
    1. Suchorska B,
    2. Giese A,
    3. Biczok A, et al

    . Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro Oncol 2018;20:279–88 doi:10.1093/neuonc/nox153 pmid:29016996

    CrossRefPubMed
69. 69.↵
    1. Zhang-Yin JT,
    2. Girard A,
    3. Bertaux M

    . What does PET imaging bring to neuro-oncology in 2022? a review. Cancers (Basel) 2022;14:879 doi:10.3390/cancers14040879 pmid:35205625

    CrossRefPubMed